Sign up Australia
Proactive Investors - Run By Investors For Investors

Benitec Biopharma’s shares ride higher after securing new U.S. patent

Research activities progressing towards new treatment options for hepatitis B.
a doctor sitting in front of a computer
patented gene-silencing technology

Benitec Biopharma Ltd’s (ASX:BLT) shares closed 20% higher on Wednesday after securing a new patent related to its hepatitis B program in the U.S.

The biotechnology company is developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi (or expressed RNAi).

The grant of this U.S. patent is an important addition to Benitec’s intellectual property portfolio and provides protection for advanced stage research activities towards new treatments for hepatitis B.

Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and cancer immunotherapy.

The ddRNAi-based therapeutics are also used for chronic and life-threatening human conditions, including OPMD, head & neck squamous cell carcinoma, retinal based diseases and hepatitis B.

Worldwide, 2 billion people (1 out of 3 people) have been infected with hepatitis B virus and 400 million people have become chronically infected, including 1 to 2 million people in the U.S.

An estimated 1 million people die each year from hepatitis B and its complications worldwide with about 5,000 of those in the U.S.

The company’s shares closed at $0.18 on Wednesday.

View full BLT profile View Profile

Benitec Biopharma Timeline

August 18 2015

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use